Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutacimig in Congenital Factor VII Deficiency
NCT07347249Phase 2Recruiting
- Sponsor
- Hemab Therapeutics
- Start
- Mar 2026
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of sutacimig in congenital factor VII deficiency (2 arms), sponsored by Hemab Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events. Started Mar 2026; status: recruiting.
02
Drugs
sutacimig
03
Conditions
congenital factor VII deficiency
Beyond the preview
Go deeper on NCT07347249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347249.